ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.
Type 2 diabetic patients treated with statins but still experiencing elevated serum levels of triglycerides (2.3 mmol/l or higher) and low HDL cholesterol (0.8 mmol/l or lower), a pre-specified subgroup, benefited from the addition of fenofibrate to their treatment regimen. Risk of cardiovascular events was reduced by 31% in those patients, translating to a need-to-treat 20 patients for five years to prevent one cardiovascular event.
J
J
Aalbers
D003226:Congresses as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D011345:Fenofibrate / Q000627:therapeutic use*; D019983:Guideline Adherence; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D017410:Practice Guidelines as Topic / Q000592:standards*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008055:Lipids; D011345:Fenofibrate